News & Insights

With a watchful eye on shifting regulatory landscapes throughout North America, how might investors or operators interpret proposed or enacted

Lengthy clinical trials and the siphoning of well-studied, ‘textbook’ psychedelics through a cumbersome medical approval regime are unnecessary in 2021,

This week, MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced a partnership with self-help guru Deepak Chopra’s The Chopra Foundation, the first high-profile,

Despite Asia’s rich history of psychedelic experience, the state of psychedelic study and commercial exploration varies widely across the continent.

Alternative health is a rising trend across all corners of the world; the global psychedelics industry is currently expected to

This week, the Multidisciplinary Association for Psychedelic Studies (MAPS) released findings from a groundbreaking Phase 3 clinical trial that suggest MDMA-assisted therapy

On 21 April 2021, hundreds of attendees from investment, science and healthcare areas attended the PSYCH Investor Summit: Europe &

This month, the Multidisciplinary Association for Psychedelic Studies (MAPS) celebrated a milestone: 35 years of research and advocacy of psychedelics. Founded in

The recent surge of interest in psychedelic medicine and research efforts has given rise to a truly 21st-century advent: psychedelic

The main exchange for listing psychedelics companies, Horizons Psychedelic Stock Index ETF, has completed its first quarterly rebalance of its holdings.

Last week, the Australian government announced it would provide $15m of funding to support research into psychedelic medicines and their

Awakn Life Sciences has opened a clinic offering ketamine-assisted psychotherapy in the UK, becoming the first of its kind in